Results from the US Food and Drug Administration (FDA)-requested analyses at Week 16 showed that a significantly higher proportion of patients achieved HiSCR50 when treated with Cosentyx 300 mg ...

Cosentyx (secukinumab) is a prescription drug for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Learn about side effects, cost, and more.

The Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab; Novartis) for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective ...

Considering positive outcomes for Cosentyx and Taltz in their respective nr-axSpA clinical trials, surveyed rheumatologists anticipate nearly doubling their current off-label use of Cosentyx and ...

ZURICH, April 24 (Reuters) - Swiss drugmaker Novartis NOVN.S on Wednesday raised its 2019 guidance after a first-quarter earnings and sales beat, as revenue from its heart failure drug Entresto ...